Propanc Biopharma Files 2024 10-K

TL;DR

Propanc Biopharma filed its 2024 10-K, detailing financials and stock info. Check it for biz health.

AI Summary

Propanc Biopharma, Inc. filed its 10-K for the fiscal year ending June 30, 2024. The company, focused on pharmaceutical preparations, reported financial data for the periods ending June 30, 2024, and June 30, 2023. The filing details various stock types, including Series B Preferred Stock and Common Stock, and related capital accounts.

Why It Matters

This filing provides a comprehensive overview of Propanc Biopharma's financial health and corporate structure for the past fiscal year, crucial for investors and stakeholders assessing the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Propanc Biopharma faces inherent risks related to drug development, regulatory approval, and market competition, which are typical for the industry.

Key Numbers

• 2024-06-30 — Fiscal Year End (Reporting period for the 10-K)
• 2023-06-30 — Prior Fiscal Year End (Comparative period in the 10-K)

Key Players & Entities

• Propanc Biopharma, Inc. (company) — Filer of the 10-K
• 2024-06-30 (date) — Fiscal year end
• 2023-06-30 (date) — Prior fiscal year end
• Series B Preferred Stock (stock) — Financial reporting item
• Common Stock (stock) — Financial reporting item

FAQ

Key Financial Figures

• $0.001 — ) of the Act: Common Stock, par value $0.001 per share Indicate by check mark if t
• $0.012 — s, Inc. on December 29, 2023 (which was $0.012 per share), based on 36,169,023 shares
• $111 billion — tic cancer market is projected to reach $111 billion by 2027. To date, recombinant trypsin

Filing Documents

• form10-k.htm (10-K) — 2471KB
• ex31-1.htm (EX-31.1) — 12KB
• ex31-2.htm (EX-31.2) — 13KB
• ex32-1.htm (EX-32.1) — 6KB
• logo_001.jpg (GRAPHIC) — 67KB
• 0001493152-24-038815.txt ( ) — 12161KB
• ppcb-20240630.xsd (EX-101.SCH) — 75KB
• ppcb-20240630_cal.xml (EX-101.CAL) — 80KB
• ppcb-20240630_def.xml (EX-101.DEF) — 370KB
• ppcb-20240630_lab.xml (EX-101.LAB) — 605KB
• ppcb-20240630_pre.xml (EX-101.PRE) — 494KB
• form10-k_htm.xml (XML) — 1808KB

Business

Business 3 Item 1A.

Risk Factors

Risk Factors 23 Item 1B. Unresolved Staff Comments 23 Item 2.

Properties

Properties 23 Item 3.

Legal Proceedings

Legal Proceedings 23 Item 4. Mine Safety Disclosure 23 Part II Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 24 Item 6. [Reserved] 25 Item 7.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 25 Item 7A.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 Item 8.

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 30 Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 31 Item 9A.

Controls and Procedures

Controls and Procedures 31 Item 9B. Other Information 33 Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 33 Part III Item 10. Directors, Executive Officers and Corporate Governance 33 Item 11.

Executive Compensation

Executive Compensation 37 Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 42 Item 13. Certain Relationships and Related Transactions, and Director Independence 44 Item 14. Principal Accounting Fees and Services 45 Part IV Item 15. Exhibits and Financial Statement Schedules 46

Signatures

Signatures 52 2 Forward-Looking This Annual Report on Form 10-K contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are "forward-looking statements" for purposes of federal and state securities laws, including: any projections of earnings, revenues or other financial items; any statements of the plans, strategies and objectives of management for future operations; any statements concerning proposed new products, services or developments; any statements regarding future economic conditions or performance; any statements of belief; and any statements of assumptions underlying any of the foregoing. Forward-looking statements may include the words "may," "might," "will," "will likely result," "would," "should," "estimate," "intend," "continue," "believe," "expect," "plan," "project," "forecast," "anticipate," "seek," "continue," "target" or the negative of such terms or other similar expressions. The ultimate correctness of these forward-looking statements is dependent upon a number of known and unknown risks and events and is subject to various uncertainties and other factors that may cause our actual results, performance or achievements to be different from any future results, performance or achievements expressed or implied by these The following important factors, among others, could affect our future results and events, causing those results and events to differ materially from those views expressed or implied in our forward-looking statements: our ability to continue as a going concern absent new debt or equity financings; our ability to successfully remediate material weaknesses in our internal controls; our ability to reach research and development milestones as planned and within proposed budgets; our ability to control costs;

View Full Filing

View this 10-K filing on SEC EDGAR